There are currently 127 clinical trials in Meridian, Idaho looking for participants to engage in research studies. Trials are conducted at various facilities, including Saint Luke's Cancer Institute - Meridian, Idaho Urologic Institute-Meridian, Solaris Clinical Research and Saint Luke's Mountain States Tumor Institute - Meridian. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
NCT03191149
Recruiting
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Idaho Urologic Institute-Meridian, Meridian, Idaho +1 locations
Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Register for Updates
A Study to Evaluate Solriktug in Adult Participants With Asthma
NCT06496607
Recruiting
Phase 2 study to evaluate the safety, tolerability, PK, immunogenicity, and pharmacodynamics of solriktug with adult participants with asthma.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2025
Locations: Research Site 022, Meridian, Idaho
Conditions: Asthma
Register for Updates
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
NCT05554380
Recruiting
This phase II ComboMATCH treatment trial tests the usual treatment of chemotherapy (paclitaxel) plus ipatasertib in patients with solid tumor cancers that that cannot be removed by surgery (unresectable), has spread to nearby tissue or lymph nodes (locally advanced) or from where it first started (primary site) to other places in the body (metastatic), and has PTEN and AKT genetic changes. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Register for Updates
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT06075667
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/22/2025
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity, Overweight
Register for Updates
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
NCT06254612
Recruiting
This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depressive Disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/18/2025
Locations: Velocity Clinical Research, Meridian, Idaho
Conditions: Major Depressive Disorder
Register for Updates
A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396236
Recruiting
The reason for this study is to see if lasmiditan is safe and effective in children aged 6 to 17 with migraine. The study will last up to 20 weeks and may include up to 4 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: St Luke's Meridian Medical Center, Meridian, Idaho +1 locations
Conditions: Migraine
Register for Updates
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
NCT04396574
Recruiting
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: St Luke's Meridian Medical Center, Meridian, Idaho +1 locations
Conditions: Migraine
Register for Updates
A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)
NCT06292013
Recruiting
The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under the skin).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/17/2025
Locations: CARE Institute, Meridian, Idaho
Conditions: Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
NCT03432286
Recruiting
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Boise, Meridian, Idaho
Conditions: Episodic Migraine
Register for Updates
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
NCT04616326
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days across the 3-month double-blind treatment period.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
04/17/2025
Locations: Velocity Clinical Research, Boise, Meridian, Idaho
Conditions: Chronic Migraine
Register for Updates
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
NCT05638295
Recruiting
This phase II ComboMATCH treatment trial tests how well AMG 510 (sotorasib) with or without panitumumab works in treating patients with KRAS G12C mutant solid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Sotorasib is in a class of medications called KRAS inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells. Pan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/11/2025
Locations: Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Conditions: Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT05040360
Recruiting
This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients wit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Saint Luke's Cancer Institute - Meridian, Meridian, Idaho
Conditions: Metastatic Malignant Neoplasm in the Liver, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor AJCC v8, Stage II Pancreatic Neuroendocrine Tumor AJCC v8, Stage III Pancreatic Neuroendocrine Tumor AJCC v8
Register for Updates